Introduction
============

Colorectal cancer (CRC) is the second leading cause of cancer-related deaths in the United States [@JR1458-1] . Screening colonoscopy has reduced CRC mortality by removing adenomas [@JR1458-2] [@JR1458-3] [@JR1458-4] . However, missed adenomas can lead to interval CRC [@JR1458-5] .

Adenoma detection rate (ADR) is a quality measure of screening colonoscopy with higher rates associated with decreased interval CRC and mortality [@JR1458-6] [@JR1458-7] [@JR1458-8] . To increase polyp detection, different devices have been designed to stabilize the colonoscope tip, and flatten haustral folds to help detect flatter, subtler lesions [@JR1458-9] . Two such devices of interest are the transparent cap and the Endocuff.

The transparent cap is a disposable, clear plastic cylinder that attaches to the colonoscope tip ( [Fig. 1](#FI1458-1){ref-type="fig"} ). Data comparing ADR between standard colonoscopy (SC) and cap-assisted colonoscopy (CAC) show modest improvement in some studies, and no difference in others [@JR1458-10] [@JR1458-11] [@JR1458-12] [@JR1458-13] [@JR1458-14] [@JR1458-15] [@JR1458-16] . Endocuff is a newer disposable device with soft projections that flatten the mucosal folds during withdrawal ( [Fig. 2](#FI1458-2){ref-type="fig"} ). Since its inception, several studies have shown significant improvements in ADR when compared to standard colonoscopy [@JR1458-17] [@JR1458-18] [@JR1458-19] .

![ Transparent cap fixed to the end of a colonoscope.](10-1055-a-0996-7891-i1458ei1){#FI1458-1}

![ Endocuff with two rows of soft projections fixed to the end of a colonoscope.](10-1055-a-0996-7891-i1458ei2){#FI1458-2}

In the current study, we aimed to compare differences in ADR between Endocuff-assisted colonoscopy (EAC), CAC and SC. To the best of our knowledge, this is the first study to compare these distal attachments with each other.

Patients and methods
====================

Study design and patient population
-----------------------------------

This was a single-center, randomized, controlled trial. The study was approved by the University of California, Davis Institutional Review Board (study no. 797109 -- 7 approved 1/7/2016). The study was registered on clinicaltrials.gov (NCT02665741). Patients aged 50 years or older scheduled to undergo average risk screening or surveillance colonoscopy at the UC Davis primary care network (PCN) clinic endoscopy suites between March 2016 and January 2017 who met eligibility criteria based on chart review were contacted prior to their procedure day and informed about the study. Exclusion criteria were: age \< 50 or \> 85 years, personal history of CRC, inflammatory bowel disease, family history of CRC in a first-degree relative younger than age 60, personal or family history of hereditary polyposis syndromes such as Lynch syndrome or familial adenomatous polyposis syndrome, pregnancy, current incarceration, inability to consent, suspicion of CRC based on noninvasive testing such as stool tests for hemoglobin or DNA, imaging finding suggestive of CRC, and patients undergoing diagnostic colonoscopy for evaluation of any gastrointestinal symptoms or signs.

Patients interested in the study received the study consent form via secured electronic medical record message or letter. After discussion with the endoscopist on the day of the procedure, patients agreeable to proceeding with the study provided written consent. Prior to patient recruitment, a randomization schedule was created using the random number generator in Excel, which assigned equal numbers of patients to each endoscopist. Each of the three endoscopists' schedule contained a unique, random, and numbered order of interventions totaling 42. The endoscopist assigned patients sequentially to either SC, EAC or CAC arms based on the randomization schedule. Study participants were blinded to the intervention.

Procedure
---------

Patients received split-dose polyethylene glycol bowel preparation. All procedures were performed using Olympus 180 high-definition white light colonoscopes (Olympus Medical Systems, Tokyo, Japan) under conscious sedation with midazolam, fentanyl or meperidine, with some patients getting diphenhydramine and/or promethazine as adjuncts. Three experienced endoscopists performed all colonoscopies. Based on patient randomization, the colonoscopes were either fitted with no distal attachment, Olympus 4-mm transparent cap (Olympus Medical Systems, Tokyo, Japan) or Endocuff (Arc Medical, Leeds, England) prior to colonoscope insertion. Bowel prep was graded using the Boston Bowel Preparation Scale (BBPS). Proximal colon was defined as colon segment proximal to the splenic flexure. Distal colon included splenic flexure and beyond. Polyp removal was by cold forceps, cold snare, or hot snare per endoscopists' discretion. All specimens were analyzed by three experienced gastrointestinal pathologists. Polyp size was as per specimen measurements in the pathology report. When fragmented, the sum of individual fragment sizes determined polyp size.

Outcomes
--------

The primary outcome was adenoma detection rate (ADR). Secondary outcomes were proximal ADR, total number of polyps detected, sessile serrated adenoma detection rate (SSADR), mean number of adenomas per colonoscopy (APC), mean adenoma per positive colonoscopy (APPC), cecal intubation rate, cecal intubation time, withdrawal time, and major complications. ADR was defined as proportion of patients with at least one tubular adenoma. APC was defined as the total number of adenomas divided by the number of colonoscopies performed. APPC was defined as the total number of adenomas divided by the total of colonoscopies where at least one adenoma was discovered.

Statistical analysis
--------------------

The required sample size of 126 (42 patients per arm) was estimated for a logistic regression model with the three-category treatment variable as the predictor and an expected 30 % increase in ADR for the transparent cap and Endocuff attachments over the control ADR of 25 % to achieve a power of 80 %. Chi square tests examined differences in gender, smoking status, diabetes, BBPS and procedure indication, between treatment arms. Normality for the continuous variables was assessed using histograms and quantiles. Alcoholic drinks per week was non-normal and tested using the Kruskal-Wallis test. All other continuous variables were approximately normal. ANOVAs were used to test for differences between the treatment group and the variables age, body-mass index, time to cecum, withdrawal time, and number of adenomas. Differences in ADR, proximal ADR, distal ADR, and SSADR were determined using chi square tests. Difference in polyp location, size, and type by treatment arm were analyzed using mixed effects regressions to control for multiple polyps per patient, and were reported as odds ratios for type and location, and as least squares means for size. Mixed effects models were fit with a random intercept and treatment as a fixed effect. We did not control for clustering within endoscopist. Categorical variables were described by frequency counts and percentages. Quantitative variables were described by mean and standard deviations. *P*  \< 0.05 was considered statistically significant. For procedure outcomes we conducted a correction to control the false discovery rate and reported the estimated q-values [@JR1458-20] . All statistical analyses were performed by MDW, an experienced statistician using SAS software version 9.4 (SAS Institute, Cary, North Carolina, United States).

Results
=======

Patient characteristics
-----------------------

A total of 126 study patients, 42 per arm, underwent colonoscopy between March 2016 and January 2017. All enrolled subjects were included in the final analysis ( [Fig. 3](#FI1458-3){ref-type="fig"} ). Patient demographics and baseline characteristics were similar across treatment groups ( [Table 1](#TB1458-1){ref-type="table"} ).

![ Consolidated Standards of Reporting Trials (CONSORT) randomization flowchart. Of the eligible patients, only 235 could be contacted by phone or medical record. All randomized patients completed the study and were analyzed.](10-1055-a-0996-7891-i1458ei3){#FI1458-3}

###### Patient demographics and baseline characteristics.

                                                SC n = 42    CAC n = 42   EAC n = 42   *P [1](#FN1458-1){ref-type="table-fn"}*
  --------------------------------------------- ------------ ------------ ------------ -----------------------------------------
  Gender                                                                               0.97
  Men, n (%)                                    23 (54.8)    24 (57.1)    23 (54.8)    
  Women, n (%)                                  19 (45.2)    18 (42.9)    19 (45.2)    
  Age, mean ± sd                                59.3 ± 7.4   60.0 ± 6.7   60.0 ± 6.8   0.87
  BMI, mean ± sd                                28.5 ± 4.3   28.3 ± 5.5   27.4 ± 5.4   0.54
  Smoking Status, n (%)                                                                0.71
  Never smoker                                  30 (71.5)    24 (57.1)    28 (66.7)    
  Former smoker                                 11 (26.1)    16 (38.1)    13 (30.9)    
  Current smoker                                1 (2.4)      2 (4.8)      1 (2.4)      
  Alcoholic drinks per week, mean ± sd          4.0 ± 3.6    6.8 ± 10.7   4.4 ± 4.0    0.86
  Diabetes, n (%)                               4 (9.5)      3 (7.1)      5 (11.9)     0.76
  Race, n (%)                                                                          0.40
  White                                         31 (73.8)    33 (78.5)    32 (76.2)    
  African-American                              1 (2.4)      1 (2.4)      1 (2.4)      
  Hispanic                                      5 (11.9)     1 (2.4)      3 (7.1)      
  Asian                                         3 (7.1)      1 (2.4)      2 (4.8)      
  Other                                         0            1 (2.4)      3 (7.1)      
  Unknown [2](#FN1458-2){ref-type="table-fn"}   2 (4.8)      5 (11.9)     1 (2.4)      

SC, standard colonoscopy; CAC, cap-assisted colonoscopy; EAC, Endocuff-assisted colonoscopy; BMI, body mass index.

Chi-square was used to determine significance with respect to gender, race, smoking, and diabetes between groups. ANOVA was used to determine significance in age, BMI and the Kruskal-Wallis test was used to test for differences in alcohol consumption between groups. *P* .05 was considered significant.

Classified as "unknown" if patient declined to state or if unavailable from the medical record

Procedure characteristics
-------------------------

BBPS and procedure indication were similar among groups ( *P*  = 0.54 and *P*  = 0.27, respectively) ( [Table 2](#TB1458-2){ref-type="table"} ). Cecal intubation was 100 % in all groups, and intubation time was similar in the SC, CAC and EAC arms at 5.6, 6 and 6.1 minutes respectively ( *P*  = 0.77). Average withdrawal time was also similar in SC, CAC and EAC groups at 12.9, 12.4 and 13.0 minutes respectively ( *P*  = 0.86) ( [Table 2](#TB1458-2){ref-type="table"} ).

###### Procedure characteristics.

                                         SC n = 42    CAC n = 42   EAC n = 42   *P **[\*](#FN1458-3){ref-type="table-fn"}***
  -------------------------------------- ------------ ------------ ------------ ----------------------------------------------
  Indication, n (%)                                                             0.29
  Screening                              27 (64.3)    32 (76.2)    33 (78.5)    
  Surveillance                           15 (35.7)    10 (23.8)    9 (21.5)     
  Boston Bowel Prep Score, mean ± sd     8.9 ± 0.5    8.9 ± 0.5    8.9 ± 0.3    0.54
  Withdrawal time (minutes), mean ± sd   12.9 ± 5.2   12.4 ± 5.6   13.0 ± 6.2   0.86
  Time to cecum (minutes), mean ± sd     5.6 ± 3.8    6.0 ± 2.8    6.1 ± 3.3    0.77

SC, standard colonoscopy; CAC, cap-assisted colonoscopy; EAC, Endocuff-assisted colonoscopy.

Chi-square test used to determine differences in procedure indication and Boston bowel prep score between groups. A mixed effects ANOVA used to determine significance in withdrawal and cecum times between groups. *P* .05 was considered significant.

Polyp detection
---------------

Overall, there was a significant difference in the total number of polyps detected between the three treatment arms ( *P*  = 0.017, q = 0.12). Both EAC (OR 4.6; 95 % CI \[1.5 -- 14.5\]) and SC (OR 3.6; 95 % CI \[1.1 -- 11.3\]) had significantly greater odds of detecting more polyps than CAC. EAC had no significant difference in polyp detection compared to SC (OR 1.29, 95 % CI \[0.4 -- 4.24\]). There was no significant difference in polyp detection rates between the proximal or distal regions of the colon between the groups ( *P*  = 0.9). There was no significant difference in mean size of polyps detected between the groups (SC 4.4 mm, CAC 5.2 mm, EAC 4.8 mm; *P*  = 0.5) ( [Table 3](#TB1458-3){ref-type="table"} ).

###### Procedure outcomes.

                                                            SC n = 42    CAC n = 42   EAC n = 42   *P [1](#FN1458-4){ref-type="table-fn"}*   Q [2](#FN1458-5){ref-type="table-fn"}
  --------------------------------------------------------- ------------ ------------ ------------ ----------------------------------------- ---------------------------------------
  Adenoma detection rate (ADR), n (%)                       22 (52.4)    17 (40.5)    23 (54.8)    0.37                                      .54
  Proximal [3](#FN1458-6){ref-type="table-fn"} ADR, n (%)   19 (45.2)    15 (35.7)    21 (50.0)    0.41                                      .54
  Distal [4](#FN1458-7){ref-type="table-fn"} ADR, n (%)     11 (26.2)    5 (11.9)     10 (23.8)    0.22                                      .51
  SSA detection rate, n (%)                                 7 (16.7)     6 (14.3)     10 (23.8)    0.50                                      .54
  Adenoma mean size (mm), mean ± SD                         4.44 ± 0.4   5.20 ± 0.5   4.75 ± 0.4   0.54                                      .54
  Mean adenoma per colonoscopy (APC)                        1.17 ± 1.3   0.76 ± 1.2   1.7 ± 2.3    0.03                                      .21
  Mean adenoma per positive colonoscopy (APPC)              2.08 ± 1.1   1.63 ± 1.4   2.6 ± 2.4    0.21                                      .51

SC, standard colonoscopy; CAC, cap-assisted colonoscopy; EAC, Endocuff-assisted colonoscopy; SSA, sessile serrated adenoma

Included all adenomas proximal to the splenic flexure

Included all adenomas distal to the splenic flexure

Chi-square test was performed to determine significance for overall ADR, ADR by location and SSADR. A mixed-effects ANOVA was used to determine differences in adenoma size between treatment arms. An ANOVA was fit using all colonoscopies to test for differences in APC and APPC between the treatment arms. A *P* -value of .05 was considered significant.

Adjusted p-value controlling for the false discovery rate.

Adenoma detection rate
----------------------

There was no significant difference in overall ADR, proximal ADR, distal ADR, or SSADR ( [Table 3](#TB1458-3){ref-type="table"} ). ADR was 52.4 %, 40.5 % and 54.8 % in the SC, CAC and EAC groups ( *P*  = 0.37). Proximal ADR showed a similar trend at 45 %, 35 %, and 50 % in each group ( *P*  = 0.41). There was no difference in distal ADR across groups with 26.2 %, 11.9 %, and 23.8 % in SC, CAC, and EAC groups, respectively ( *P*  = 0.22). SSA detection rate was also similar at 16 %, 14 %, and 23 % respectively ( *P*  = 0.50) ( [Table 3](#TB1458-3){ref-type="table"} ). There was a numeric difference between EAC and CAC among all ADR outcomes, but it was not significant ( [Table 3](#TB1458-3){ref-type="table"} ).

Adenomas
--------

The mean number of adenomas per colonoscopy was 1.17, 0.76 and 1.7 in the SC, CAC and EAC groups ( [Table 3](#TB1458-3){ref-type="table"} ). There was no significant difference in the means when comparing either device to non-device assisted screening colonoscopy (SC); however, EAC demonstrated a significantly higher mean adenoma per colonoscopy compared to CAC (1.7 vs. 0.76; *P*  = 0.01) ( [Table 3](#TB1458-3){ref-type="table"} ). When analyzing adenomas per positive colonoscopy, there was no difference between the three groups (SC 2.08 vs. CAC 1.63 vs EAC 2.6; *P*  = 0.21) ( [Table 3](#TB1458-3){ref-type="table"} ).

Complications and adverse events
--------------------------------

Two patients in the Endocuff arm developed post-polypectomy bleeding and required repeat colonoscopy to achieve hemostasis.

Discussion
==========

This is the first randomized study to compare both CAC and EAC to SC. We found no significant improvement with either device compared to SC with respect to ADR, proximal and distal ADR, SSADR, mean adenoma per procedure and mean adenomas per positive colonoscopy. Both EAC and SC detected a greater number of polyps than CAC, and EAC demonstrated a significantly higher mean adenoma per procedure compared to CAC. However, when this was corrected to control for the false-discovery rate, these did not reach statistical significance. Overall there was a trend towards EAC being better than CAC in all study metrics without reaching statistical significance.

Current American Society for Gastrointestinal Endoscopy and American College of Gastroenterology screening guidelines for average-risk patients recommend an overall ADR of 25 %, 30 % for men and 20 % for women [@JR1458-21] . In our study, all treatment arms demonstrated a higher-than-recommended ADR, indicating that all patients received a high-quality examination regardless of attachment.

Previous ADR studies with CAC have shown mixed results compared to SC [@JR1458-10] [@JR1458-12] [@JR1458-14] [@JR1458-15] [@JR1458-22] [@JR1458-23] [@JR1458-24] . Most earlier studies included patients outside of the average-risk colon cancer screening age range, and indications not just limited to CRC screening or colon adenoma surveillance. A large meta-analysis carried out by Ng and colleagues analyzed 12 randomized studies comparing CAC to SC, and found that CAC was superior to SC in detecting all polyps, but there were no difference in ADR [@JR1458-13] .

Previous studies comparing EAC to SC have shown a more consistent improvement in ADR than those of CAC. EAC has shown to increase overall polyp detection rate, ADR and higher adenomas per patient compared to standard therapy [@JR1458-17] [@JR1458-19] [@JR1458-25] . But these studies contained a large number of diagnostic and surveillance colonoscopies, which makes it difficult to generalize to an average-risk screening population. A recent meta-analysis by Chin et al examined eight retrospective and randomized studies and found a significantly higher ADR with EAC compared to SC [@JR1458-26] . Moreover, a tandem colonoscopy study found that EAC detected 20 % more adenomas compared to SC [@JR1458-18] . Tandem colonoscopy studies report adenoma miss rates up to 25 %, which could lead to interval CRC [@JR1458-27] . Hence, EAC may help with reducing interval CRC, but more long-term follow-up studies are needed.

We found no difference in ADR between SC and EAC. Given the high ADR in the control group, we retrospectively reviewed the pre-study ADR of each endoscopist and found that the baseline ADR was 43 %, 48 % and 55 %, respectively. Based on the high pre-study ADR and large effect size, our study was likely underpowered to detect a significant difference between the groups. Moreover, our results may also indicate that adding the Endocuff confers no additional benefit for high adenoma detectors.

Interestingly we noted CAC to underperform SC among all endoscopists in all metrics including ADR, despite similar baseline and procedure characteristics. There have been no published studies establishing a learning curve with the transparent cap but there appears to be some benefit with successive use [@JR1458-28] . A pre-study training period with transparent cap has also varied between three and 20 in previous studies [@JR1458-10] [@JR1458-14] [@JR1458-15] . We did not employ pre-study training, and the study endoscopists did not routinely use the transparent cap in their practices. Though unclear, relative inexperience and technical challenges could account for the lower ADR in the CAC group. 

Improvement in proximal ADR is an area of great interest. The proximal colon poses challenges for adenoma detection due to more prominent haustrae, flat and/or subtler lesions, and differences in bowel prep. Missed adenomas are more likely in the proximal colon, and may explain the higher protective effect of screening colonoscopy against cancer in the distal colon [@JR1458-5] [@JR1458-29] [@JR1458-30] [@JR1458-31] . Devices that can increase detection of adenomas in the proximal colon may be of substantial benefit. We found no difference between EAC and SC in proximal ADR. There was a trend towards both outperforming CAC in the proximal colon. A recent meta-analysis found that the transparent cap detected more proximal adenomas per patient compared to standard colonoscopy, and the adenomas tended to be diminutive [@JR1458-32] . EAC has also demonstrated an increased ADR in the cecum and ascending colon in earlier studies, and higher odds of proximal adenoma detection [@JR1458-17] [@JR1458-19] [@JR1458-26] . To date, there have been no EAC or CAC studies to our knowledge with proximal ADR as a primary endpoint.

We also examined differences in SSADR. SSA have a predilection for the proximal colon and may be harder to detect due to more subtle features [@JR1458-33] [@JR1458-34] [@JR1458-35] [@JR1458-36] . Retrospective studies report varying prevalence of SSAs between 4 % to 13 %, and higher SSADR has a stronger correlation with the endoscopist versus other factors such as age and gender [@JR1458-37] [@JR1458-38] [@JR1458-39] [@JR1458-40] . Based on an overall ADR of 20 %, it is thought that corresponding SSADR should be 5 % [@JR1458-38] . We found that in all three groups, SSADR exceeded this threshold, which likely corresponds to our endoscopists' overall high ADR. While EAC demonstrated a higher SSADR compared to SC and CAC, this was not statistically significant. A meta-analysis of three studies by Desai et al suggested that CAC may detect more SSAs than standard colonoscopy [@JR1458-32] . Our data suggests that EAC may improve SSA detection. Adequately powered studies in the future may help determine if either EAC or CAC are superior to SC in terms of SSADR.

APC and mean APPC are additional quality metrics for screening colonoscopy given limitations of ADR [@JR1458-41] [@JR1458-42] [@JR1458-43] . APC may correlate well with endoscopists who are high detectors, while APPC may have more correlation over a wide range of ADR [@JR1458-42] . Higher APC and APPC likely correlate with a more thorough exam. When uncorrected for the false discovery rate, we found that EAC had a significantly better APC than CAC, and detected 46 % more adenomas per procedure (1.7 vs. 1.17) compared to SC but was not statistically significant. Similar findings but to a lesser magnitude were noted with APPC, where EAC detected 49 % and 17 % more adenomas per positive colonoscopy than CAC and SC, respectively. Our study was not adequately powered to detect these differences, but it does suggest that EAC may detect more adenomas in patients with at least one adenoma.

There was no difference in mean adenoma size between the groups, probably because mean adenoma size in all groups was diminutive. While some earlier studies have indicated higher detection and lower miss rates for diminutive adenomas using either EAC or CAC, others have shown no difference [@JR1458-10] [@JR1458-11] [@JR1458-17] [@JR1458-18] [@JR1458-19] [@JR1458-24] [@JR1458-25] [@JR1458-44] [@JR1458-45] .

Two study patients developed post-polypectomy bleeding after undergoing EAC, which is unlikely to be related to the device. While prior studies reported higher risk of minor mucosal tearing due to the double row of projections of endocuff, we did not observe this [@JR1458-17] [@JR1458-19] .

There are limitations to our study. First, it was single-center study with a relatively small sample size. Our endoscopists were not blinded, but this was likely not a significant factor given the lack of statistically significant differences in ADR between treatment groups. Our high pre-study ADR and sample size calculated to detect a 30 % difference in the primary endpoint of ADR likely prevented us from detecting a statistically significant difference between groups. We were not able to study if the transparent cap or the Endocuff may improve ADR among trainees or endoscopists with lower than recommended ADR. By measuring polyp size based on specimen measurements in the pathology lab, we may have underestimated polyp size due to tissue shrinkage in formalin.

The strengths of our study reside in its prospective randomized controlled design, outpatient setting, inclusion of only screening and surveillance colonoscopies, split-dose bowel preparation, and uniformly excellent prep quality. Withdrawal times were on average twice the recommended duration of 6 minutes in all arms, though it should be noted that the time taken to perform polypectomy is included within the withdrawal time [@JR1458-21] . Study population was inclusive of both genders, and all major races/ethnicities. Moreover, our subjects and procedure indications are applicable to the majority of gastroenterology practices in the Western world.

During our clinical trial, Endocuff was replaced by a newer version called Endocuff Vision, which has a single row of slightly longer finger-like projections. In a recent non-randomized study of fecal immunochemical test-positive patients, endoscopists found a higher mean ADR with Endocuff Vision [@JR1458-46] . But a randomized UK study found no difference in ADR between Endocuff Vision and standard colonoscopy [@JR1458-47] . The ADR was 63 % in the SC arm, suggesting limited benefit of endocuff when ADR is already high.

A decision to use any device to increase ADR should consider the potential benefit and overall cost of intervention. To date, no cost-benefit analysis has been performed on either CAC or EAC.

Conclusion
==========

In conclusion, we presented the first randomized study to compare two popular distal colonoscope attachments, the transparent cap and Endocuff, with SC, and found no significant benefit with either device over a good-quality SC by experienced endoscopists. Future studies may help determine if either device confers a benefit in ADR, especially among low adenoma detectors.
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